companydata.dkXELLIA PHARMACEUTICALS ApS
CVR: 61094628
Secondary names: AXELLIA PHARMACEUTICALS ApS
Xellia Pharmaceuticals ApS has experienced a significant turnaround in financial health from 2023 to 2024, achieving a revenue of 1.6 billion DKK and a profit of 829 million DKK, a stark contrast to the previous year's loss of 2.4 billion DKK. However, the company's equity remains low at 162 million DKK, following a decline from 2.6 billion DKK in 2020, indicating ongoing concerns about its financial stability. The revenue trend shows a decline from 2022's peak of 2.2 billion DKK, highlighting potential challenges in maintaining market position within the pharmaceutical raw materials industry. Overall, while profitability has improved, the equity position and historical losses raise concerns about long-term sustainability.
AI-generated summary
Overview
- Company type
- APS
- Anpartsselskab
- Founded
- 31.3.1959
Details
- Industry
- Fremstilling af farmaceutiske råvarer
- Code: 211000
- Secondary industries
- Fremstilling af farmaceutiske præparater (212000)
- Employees
- 595 employees
- 581 FTE
- (2018)
- Capital
- 201.000.000 kr.
Contact
- Phone
- Log in to see
Purpose
Selskabets formål er at drive fabrikation af og handel med medicinalvarer til human eller veterinær brug, finkemikalier, kosmetik, forskning og udvikling samt hermed beslægtet virksomhed enten direkte eller ved anbringelse af kapital i selskaber med ligende formål samt at virke som repræsentant eller alliancepartner for danske og udenlandske virksomheder inden for sådanne forretningsområder.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1.6 mia. | 829 mio. | 3.2 mia. | 162.5 mio. | 547 | |
History
Ownership
Properties
(5)· 2 historic5 properties
Upgrade to Pro to see addresses, building data and ownership details
Management
Directors
Board
Production units (3)
Similar companies
Companies in the same industry and area